Medical implants with increased hydrophilicity

Information

  • Patent Grant
  • 9375321
  • Patent Number
    9,375,321
  • Date Filed
    Tuesday, August 11, 2015
    8 years ago
  • Date Issued
    Tuesday, June 28, 2016
    8 years ago
Abstract
Devices such as orthopedic implants are composed of a thermoplastic resin such as polyaryletheretherketone (PEEK), and include a ceramic species, such as a zeolite, to enhance its hydrophilic properties. The ceramic species can be a surface coating, can be incorporated or embedded into the thermoplastic resin, or can be both a surface coating and incorporated or embedded into the resin. In certain embodiments, the ceramic species is zeolite that is incorporated into the device, especially at the exposed surface of the device, and is devoid of antimicrobial metal ions. The device is introduced into the body surgically.
Description
BACKGROUND

Implantable medical devices are implanted into the body for various reasons including orthopedic applications (e.g., hip replacement, spinal procedures, knee replacement, bone fracture repair, etc). In view of the structural integrity required by such devices, materials of fabrication are limited and generally consist of metal, plastic and composites.


The benefits derived from these devices are often offset by infection which in some cases can lead to sepsis and death. The most common organisms causing infections are Staphylococcus epidermidis and Staphylococcus aureus. Staphylococcus epidermidis is a major component of the normal bacterial flora of human skin and mucous membranes. It is a common pathogen that often colonizes patients in hospital settings who have surgical implants due to the microbes' ability to adhere to medical devices and form a biofilm. Additionally, methicillin-resistant Staphylococcus aureus (MRSA) is a type of staphylococcus bacteria that is resistant to many antibiotics is therefore of particular concern. Other gram-positive bacteria, gram-negative bacteria and fungal organisms also are causative organisms that may be problematic.


As microorganisms come in close proximity to the surface of the medical device, they will either be attracted or repelled by it depending on the sum of the different non-specific interactions. In biological systems, hydrophobic/hydrophilic interactions play an important role in the pathogenesis of a wide range of microbial infections.


Many bacteria can form multicellular coatings, or biofilms, on bioengineered implants. Biofilms facilitate the proliferation and transmission of microorganisms by providing a stable and protective environment for their growth. These biofilms may often result in a broad systemic infection.


In many instances, when implants are seeded by organisms which are protected by tenacious biofilms, the implant must be removed and the patient must be treated with a prolonged course of one or more antibiotics in an effort to cure the infection, after which time a new implant is then reimplanted. This process not only subjects the patient to additional trauma and pain but is also extremely expensive.


Not surprising, a great deal of research has been devoted toward preventing the colonization of the surfaces of orthopedic implants by bacterial and fungal organisms with the use of antimicrobial agents such as antibiotics which may be bound to the surface of these devices.


Thermoplastic resins including polyetherketoneketone (PEKK) and polyetheretherketone (PEEK) have been found to be a useful material for these implants. PEEK is particularly suitable because its modulus of elasticity closely matches that of bone. However, PEEK is a hydrophobic material and bacteria tend to adhere easily to these types of surfaces. It is also an organic material which does not carry significant surface charges. Consequently, it may be desirable to develop a medical implant composed of one or more thermoplastic resins that has reduced hydrophobic properties, and/or that has a net negative charge, particularly at an exposed surface when implanted.


SUMMARY

The shortcomings of the prior art have been overcome by the embodiments disclosed herein, which relate to devices, such as structural orthobiologic materials, particularly intracorporeal devices such as surgical implants, more particularly orthopedic implants, even more particularly spinal implants. In certain embodiments, the device is osteoconductive and is comprised of a thermoplastic resin such as polyaryletheretherketone (PEEK) or polyetherketoneketone (PEKK), and includes a ceramic species, such as a zeolite, to add hydrophilicity and/or a negative charge to the resin. The ceramic species is devoid of antimicrobial metal ions such as silver, copper, zinc, mercury, tin, lead, gold, bismuth, cadmium, chromium and thallium ions. The ceramic species can be a surface coating, can be incorporated or embedded into the thermoplastic resin, or can be both a surface coating and incorporated or embedded into the resin.


In certain embodiments, the ceramic species is zeolite that is incorporated into the device, especially at the exposed surface of the device. The device is introduced into the body surgically. Radio opacity when viewed under X-ray is retained.







DETAILED DESCRIPTION

Embodiments disclosed herein relate to the use of ceramics in combination with medical implants comprising thermoplastic resins such as PEEK, PEKK or the like to alter the hydrophobicity of the polymer and impart a negative charge to the polymer such as at an exposed surface of the polymer, in order to minimize or eliminate biofilm formation, and/or to disrupt the integrity of the biofilm and thus its ability to protect bacteria.


Although the present inventors do not intend to be bound to any particular theory of operation, it is believed that biofilms develop because bacteria attach to the implant. The hydrophobic properties of the implant (now with attached bacteria) prevent antimicrobials from attacking the biofilm containing bacteria. The PEEK/zeolite combination with ionic properties, increases the ability of antimicrobial moieties to permeate in and kill the bacterial pathogen rather than be repelled by the hydrophobic surface properties of naked PEEK.


All bacteria adhere better to hydrophobic surfaces, and it also may be more difficult to detach bacteria from hydrophobic surfaces.


The first stage of bone formation is protein adsorption. Typically, proteins that are most important (i.e., RGD peptide) for bone forming cells attach to surfaces that are negatively charged. Additionally, the charged surface allows the proteins to attach in the correct conformation, leading to the attachment of an optimal number of proteins. The Second stage of bone formation is the attachment of pre-osteoblast cells to the adsorped proteins. These cells then form mature osteoblasts, spread phyllopodia and start the osteoblast maturation/proliferation process. Mature osteoblasts produce ECM (extra cellular matrix) which in combination with the cells, mineralizes into woven bone. PEEK is highly hydrophobic which prevents protein adsorption without which the bone forming process cannot start. By incorporating zeolite into the PEEK structure, a negatively charged surface is created which has the potential to initiate the protein adsorption process.


In addition, tissue does not adhere well to pure PEEK; the tissue simply grows up against the PEEK and forms an interface with minimal adhesion between the two materials. This interface provides an area which is very susceptible to formation of bacterial biofilms, even from systemic bacteria which arrive long after surgery. Since the hydrophilic nature and/or charges on the surface of composite of PEEK and ceramics such as zeolite will foster the growth and adhesion of fibroblasts and osteoblasts that interact with developing tissue, the interface will disappear soon after surgery and the potential for biofilm there will be greatly reduced or even eliminated.


In certain embodiments, the device is configured for use in spinal fusion (arthrodesis) which is often employed to stabilize an unstable spinal column due to structural deformity, trauma, degeneration, etc. Fusion is a surgical technique in which one or more vertebrae of the spine are united together (“fused”) to reduce or eliminate relative motion between them or to fix the spatial relationship between them. Spinal fusions include posterolateral fusion, posterior lumbar interbody fusion, anterior lumbar interbody fusion, anterior/posterior spinal fusion, cervical fusion, thoracic fusion and interlaminar fusion. In certain embodiments, the devices are for insertion in an intervertebral space between adjacent vertebrae. In certain embodiments, a fusion site is identified between adjacent vertebrae and a bone graft is implanted at said site. In certain embodiments, the implant is a spinal interbody cage, including cages comprising titanium, carbon fibers, biocompatible materials such as polyetheretherketone (PEEK), polyetherketoneketone (PEKK), or other synthetic substances. In certain embodiments, zeolite particles are incorporated into the PEEK interbody cage. In certain embodiments, the cage is loaded with osteoconductive and/or osteoinductive agents to promote fusion. Preferably, ceramic particles are incorporated into the resin such that a negative charge is imparted to an exposed surface of the resin. The term “exposed surface” is intended to include one or more surfaces of an implantable device that when implanted, is exposed to or in contact with body tissue and/or fluids.


Either natural zeolites or synthetic zeolites can be used to make the zeolites used in the embodiments disclosed herein. “Zeolite” is an aluminosilicate having a three dimensional skeletal structure that is represented by the formula: XM2/nO.Al2O3.YsiO2.ZH2O, wherein M represents an ion-exchangeable ion, generally a monovalent or divalent metal ion, n represents the atomic valency of the (metal) ion, X and Y represent coefficients of metal oxide and silica respectively, and Z represents the number of water of crystallization. Examples of such zeolites include A-type zeolites, X-type zeolites, Y-type zeolites, T-type zeolites, high-silica zeolites, sodalite, mordenite, analcite, clinoptilolite, chabazite and erionite.


Zeolites can be obtained in master batches of pellets of low density polyethylene, polypropylene, ultra high molecular weight polyethylene or polystyrene, containing suitable amounts of zeolite particles, usually 20 wt. % of zeolite particles. When provided in this form, the pellets of resin containing the zeolite particles can be easily mixed with resins used to make the implants or used to make coatings to be applied to the implants, as set forth in U.S. Pat. No. 6,582,715, the disclosure of which is hereby incorporated by reference. Typical amounts of zeolite particles incorporated in an implant resin range from 0.01 to 10 wt. %, more preferably 0.01 to 8.0 wt. %, most preferably 0.1 to 5.0 wt. %. The method used to coat or otherwise incorporate the ceramic in to the resin is not particularly limited, and can include spraying, painting or dipping. When compounded into PEEK, for example, the PEEK should be protected from sources of moisture and contamination. The compounding can be carried out by blending. The ceramic species can be a surface coating, can be incorporated or embedded into the thermoplastic resin, or can be both a surface coating and incorporated or embedded into the resin.


Other suitable resins include low density polyethylene, polypropylene, ultra high molecular weight polyethylene or polystyrene, polyvinyl chloride, ABS resins, silicones, rubber, and mixtures thereof. These can be formulated to contain suitable amounts of zeolite particles, usually about 20 wt. %. An UHMWPE is preferred for the implant devices.


The masterbatch is a concentrated mixture of pigments and/or additives (e.g., zeolite powder) encapsulated during a heat process into a carrier resin which is then cooled and cut into a granular shape. Using a masterbatch allows the processor to introduce additives to raw polymer (let down resin) economically and simply during the plastics manufacturing process.


The zeolite incorporated into the resin and implanted is devoid of antimicrobial metal ions.


Under conditions of high temperature and high shear, the zeolite is incorporated into the resin, such as by mixing doped metal zeolites into molten PEEK (melting point between 300 and 400° C.), followed by molding and processing of the composite blend.


EXAMPLE

About 5% by weight of the zeolite powder is mixed thoroughly with the powdered or prilled PEEK. The mixture is brought up to temperature and processed at 400° C. using high shear. The zeolite and PEEK must be dry before processing in order to minimize decomposition and void formation in the product.


The material can be formed into prills for further processing, cast into blocks, extruded into rods or injection molded into the final desired shapes.


The block and rod materials can be machined into shapes which are suitable for use as orthopedic implants or other designs where antimicrobial PEEK finds application. Implants can be designed to provide enhanced surface area by having grooves cut in the surfaces or by producing products with holes in the body of the pieces. Surface area can be further enhanced by sanding or abrasive blasting of the surfaces.

Claims
  • 1. A method of initiating bone formation, comprising implanting in said patient a device comprising a thermoplastic resin having aluminosilicate particles incorporated therein, said aluminosilicate particles being devoid of antimicrobial metal ions and being present in said coating in an amount sufficient to initiate protein adsorption on said implant.
  • 2. The method of claim 1, wherein said thermoplastic resin comprises PEEK.
  • 3. The method of claim 1, wherein said implant is an interbody spinal cage.
  • 4. The method of claim 1, wherein said aluminosilicate is represented by the formula XM2/nO.Al2O3.YsiO2.ZH2O wherein M represents an ion-exchangeable ion, n represents the atomic valency of the (metal) ion, X and Y represent coefficients of metal oxide and silica respectively, and Z represents the number of water of crystallization.
Parent Case Info

This application is a Continuation of U.S. patent application Ser. No. 13/696,346 filed Nov. 27, 2012, the disclosure of which is incorporated herein by reference, which is a 371 of PCT/US2011/035468 filed May 6, 2011, which claims priority of U.S. Provisional Application Ser. No. 61/332,403 filed May 7, 2010, the disclosure of which is incorporated herein by reference.

US Referenced Citations (106)
Number Name Date Kind
4088737 Thomas et al. May 1978 A
4596574 Urist Jun 1986 A
4612337 Fox et al. Sep 1986 A
4615705 Scales et al. Oct 1986 A
4775585 Hagiwara et al. Oct 1988 A
4775586 Bohrn et al. Oct 1988 A
4861808 Billington et al. Aug 1989 A
4906464 Yamamoto et al. Mar 1990 A
4911898 Hagiwara et al. Mar 1990 A
4911899 Hagiwara et al. Mar 1990 A
4923450 Maeda et al. May 1990 A
4938955 Niira et al. Jul 1990 A
4938958 Niira et al. Jul 1990 A
4957817 Chau et al. Sep 1990 A
4959268 Hagiwara et al. Sep 1990 A
5003638 Miyake et al. Apr 1991 A
5100671 Maeda et al. Mar 1992 A
5151122 Atsumi et al. Sep 1992 A
5180585 Jacobson et al. Jan 1993 A
5192590 Sherman Mar 1993 A
5256390 Hu Oct 1993 A
5266534 Atsumi et al. Nov 1993 A
5294634 Yamaguchi Mar 1994 A
5296238 Sugiura et al. Mar 1994 A
5474797 Sioshansi et al. Dec 1995 A
5478563 Erami Dec 1995 A
5492763 Barry et al. Feb 1996 A
5522904 Moran et al. Jun 1996 A
5556699 Niira et al. Sep 1996 A
5595750 Jacobson et al. Jan 1997 A
5607464 Trescony et al. Mar 1997 A
5609629 Fearnot et al. Mar 1997 A
5614568 Mawatari et al. Mar 1997 A
5647858 Davidson Jul 1997 A
5688561 Ichikawa et al. Nov 1997 A
5709870 Yoshimura et al. Jan 1998 A
5731087 Fan et al. Mar 1998 A
5753251 Burrell et al. May 1998 A
5756145 Darouiche May 1998 A
5770255 Burrell et al. Jun 1998 A
5783570 Yokota et al. Jul 1998 A
6015816 Kostyniak et al. Jan 2000 A
6090732 Ito et al. Jul 2000 A
6180606 Chen et al. Jan 2001 B1
6248342 Trogolo et al. Jun 2001 B1
6267590 Barry et al. Jul 2001 B1
6296863 Trogolo et al. Oct 2001 B1
6436422 Trogolo et al. Aug 2002 B1
6471993 Shastri et al. Oct 2002 B1
6582715 Barry et al. Jun 2003 B1
6585767 Holley et al. Jul 2003 B1
6720006 Hanke et al. Apr 2004 B2
6723428 Foss et al. Apr 2004 B1
6866859 Trogolo et al. Mar 2005 B2
6946196 Foss Sep 2005 B2
6984392 Bechert et al. Jan 2006 B2
6994883 Layrolle et al. Feb 2006 B2
7270813 Shimp et al. Sep 2007 B2
7354605 Trogolo et al. Apr 2008 B2
7357949 Trogolo et al. Apr 2008 B2
8652645 Dingeldein et al. Feb 2014 B2
8821912 Crudden et al. Sep 2014 B2
8840914 Crudden et al. Sep 2014 B2
9107765 Ghiselli et al. Aug 2015 B2
9132576 Crudden et al. Sep 2015 B2
20020099449 Speitling Jul 2002 A1
20030031687 Falder et al. Feb 2003 A1
20040109937 Jennissen et al. Jun 2004 A1
20050058682 Sharratt Mar 2005 A1
20050064176 Terry Mar 2005 A1
20050149196 Zucherman et al. Jul 2005 A1
20050170070 Layrolle et al. Aug 2005 A1
20050203529 Boehm et al. Sep 2005 A1
20060052479 Cougoulic Mar 2006 A1
20060069438 Zucherman et al. Mar 2006 A1
20060161256 Ziegler et al. Jul 2006 A1
20060177379 Asgari Aug 2006 A1
20060259020 Sharratt Nov 2006 A1
20060265065 Bagga et al. Nov 2006 A1
20060280803 Kumar et al. Dec 2006 A1
20070015110 Zhang et al. Jan 2007 A1
20070031515 Stucky et al. Feb 2007 A1
20070110825 Taniguchi et al. May 2007 A1
20070267029 Mason Nov 2007 A1
20070276337 Trieu Nov 2007 A1
20070299472 Brighton Dec 2007 A1
20080032119 Feldhahn et al. Feb 2008 A1
20080032572 Burgoyne Feb 2008 A1
20080063671 Morris et al. Mar 2008 A1
20080208340 Boyd et al. Aug 2008 A1
20080249637 Asgari Oct 2008 A1
20080258337 Ajbani et al. Oct 2008 A1
20090012612 White et al. Jan 2009 A1
20090238850 Greener Sep 2009 A1
20100010632 Bourges et al. Jan 2010 A1
20100099058 Wang Apr 2010 A1
20100114317 Lambrecht et al. May 2010 A1
20100215643 Clevenger et al. Aug 2010 A1
20110022181 Kasahara et al. Jan 2011 A1
20120141599 Johns et al. Jun 2012 A1
20120315340 Crudden et al. Dec 2012 A1
20120323339 Graells et al. Dec 2012 A1
20130004585 Crudden et al. Jan 2013 A1
20130037991 Crudden et al. Feb 2013 A1
20130073042 Ghiselli et al. Mar 2013 A1
20140366362 Crudden et al. Dec 2014 A1
Foreign Referenced Citations (35)
Number Date Country
11260 Oct 2008 BY
2171703 Apr 1995 CA
1732025 Feb 2006 CN
100360193 Jan 2008 CN
101234304 Aug 2008 CN
101238166 Aug 2008 CN
3228849 Feb 1984 DE
10055465 May 2002 DE
011594 Apr 2009 EA
0116865 Aug 1984 EP
0253663 Jan 1988 EP
0722660 Jul 1996 EP
1813292 Aug 2007 EP
2848856 Jun 2004 FR
2512324 May 1990 JP
2003-513682 Apr 2003 JP
2004-523302 Aug 2004 JP
10-2009-0031668 Mar 2009 KR
2313370 Dec 2007 RU
2338557 Nov 2008 RU
8401721 May 1984 WO
9907326 Feb 1999 WO
0030697 Jun 2000 WO
0032247 Jun 2000 WO
0064505 Nov 2000 WO
03086495 Oct 2003 WO
2004058319 Jul 2004 WO
2006069677 Jul 2006 WO
2007019461 Feb 2007 WO
2008037751 Apr 2008 WO
2008039488 Apr 2008 WO
2008150867 Dec 2008 WO
2009099559 Aug 2009 WO
2010114827 Oct 2010 WO
2014152649 Sep 2014 WO
Non-Patent Literature Citations (78)
Entry
International Search Report/Written Opinion mailed May 13, 2010 in co-pending PCT application No. PCT/US 10/29180.
International Preliminary Report on Patentability dated Dec. 6, 2011 in co-pending PCT application No. PCT/US 10/29180.
Chinese Communication issued Sep. 26, 2012 in co-pending Chinese patent application No. CN 201080015851.3.
European communication mailed Feb. 6, 2014 in co-pending European patent application No. 10759287.5.
Russian Communication, with English translation, issued Oct. 9, 2013 in co-pending Russian patent application No. RU 2011144020.
Russian communication dated Apr. 14, 2014 in co-pending Russian patent application No. 2011144020/15(066044).
European communication dated Oct. 7, 2015 in co-pending European patent application No. 15163787.3.
Korean communication, with English translation, dated Jan. 12, 2016 in co-pending Korean patent application No. 10-2011-7023593.
International Search Report and Written Opinion mailed Aug. 19, 2011 in co-pending PCT application No. PCT/US2010/058009.
International Preliminary Report on Patentability mailed Jun. 7, 2012 in co-pending PCT application No. PCT/US2010/058009.
Extended European Search Report mailed May 21, 2013 in co-pending European patent application No. EP 10833925.0.
Chinese Communication issued Dec. 3, 2013 in co-pending Chinese patent application No. CN 201080062338.X.
Chinese communication, with English translation, issued Jul. 1, 2014 in co-pending Chinese patent application No. 201080062338.X.
Chinese communication, with English translation, issued Sep. 30, 2014 in co-pending Chinese patent application No. 201080062338.X.
Russian communication, with English translation, dated Sep. 15, 2014 in co-pending Russian patent application No. 2012126078/15(040280).
Russian Communication, with English translation, issued Jan. 12, 2015 in co-pending Russian patent application 2012126078/15(040280).
International Search Report and Written Opinion mailed Aug. 25, 2011 in co-pending PCT application No. PCT/US2010/059868.
International Preliminary Report on Patentability mailed Jun. 21, 2012 in co-pending PCT application No. PCT/US2010/059868.
European Communication mailed Aug. 27, 2013 in co-pending European patent application No. EP 10836743.4.
European communication dated May 27, 2015 in co-pending European patent application No. 10836743.4.
English translation of Chinese Communication issued Oct. 30, 2013 in co-pending Chinese patent application No. CN 201080063584.7.
Chinese communication, with English translation, issued Jun. 17, 2014 in co-pending Chinese patent application No. CN 201080063584.7.
Russian Communication, with English translation, issued Nov. 20, 2013 in co-pending Russian patent application No. RU 2012129171.
Russian communication dated Apr. 17, 2014 in co-pending Russian patent application No. 2012129171/15(045686).
European communication dated Oct. 27, 2015 in co-pending European patent application No. 10836743.4.
International Search Report and Written Opinion mailed Jan. 9, 2012 in corresponding PCT application No. PCT/US2011/035468.
International Preliminary Report on Patentability mailed Aug. 7, 2012 in corresponding PCT application No. PCT/US2011/035468.
European Communication mailed Sep. 4, 2013 in corresponding European patent application No. EP 11778401.7.
Canadian communication dated Apr. 9, 2014 in corresponding Canadian patent application No. 2,795,836.
Chinese Communication issued Jan. 6, 2014 in corresponding Chinese patent application No. CN 201180023035.1.
Chinese communication, with English translation, issued Jul. 7, 2014 in corresponding Chinese patent application No. 201180023035.1.
Chinese communication, with English translation, mailed Mar. 30, 2015 in corresponding Chinese patent application No. 201180023035.1.
Mexican communication, with English translation, dated Apr. 17, 2015 in corresponding Mexican patent application No. MX/a/2012/012710.
Russian communication, with English translation, dated Jun. 3, 2015 in corresponding Russian patent application No. 2012152640.
Chinese communication, with English translation, dated Oct. 10, 2015 in corresponding Chinese patent application No. 201180023035.1.
Russian communication, with English Translation, dated Dec. 28, 2015 in corresponding Russian patent application No. 2012152640.
International Search Report and Written Opinion mailed Jul. 21, 2014 in co-pending PCT application No. PCT/US14/27576.
International Preliminary Report on Patentability mailed Apr. 8, 2015 in co-pending PCT application No. PCT/US14/27576.
Antimicrobial Agents and Chemotherapy, Dec. 2005, vol. 49, No. 12, pp. 4853-4859, “Role of Silver Ions in Destabilization of Intermolecular Adhesion Forces Measured by Atomic Force Microscopy in Staphylococcus epidermidis Biofilms”, CHAW, et al.
Journal of the Brazilian Chemical Society, vol. 19, No. 1, Sao Paolo, 2008, pp. 1-11, downloaded from the interenet Mar. 1, 2013, “Preparation and characterization of poly(ether ether ketone) derivatives”, Conceicao, et al.
DiFusion Technologies research paper, created Oct. 14, 2013, “Novel Orthopedic Implant Material Protects Osteoblast Viability in the Presence of Biofilm-Forming MRSA”, 4 pages.
Emerging Infectious Diseases, vol. 7, No. 2, Mar.-Apr. 2001, pp. 277-281, “Biofilms and Device-Associated Infections”, Donlan.
Clinical Microbiology Reviews, Apr. 2002, vol. 15, No. 2, pp. 155-166, Focus, “Bacterial Adhesion: Seen Any Good Biofilms Lately?”, Dunne, Jr., et al.
“Antimicrobial Efficacy of a novel Orthobiologic PEEK in treating Surgical Site Spine Infections”, http://www.difusiontech.com/wp-content/uploads/NASS-Summer-Conference—2013-Abstract—final2.pdf, NASS Summer Session, Aug. 2-5, 2013, Naples, FL, 2 pages, EASTLACK, et al.
“Exploring the efficacy of a self-sterilizing orthobiologic PEEK as a viable biomaterial for spinal surgery”, http://www.nassannualmeeting.org/Documents/AMB—FinalProgram.pdf, Abstract, NASS Annual Meeting, Oct. 9-12, 2013 NewOrleans, LA, 3 pages, EASTLACK, et al.
The Journal of Biological Chemistry, vol. 263, No. 13, May 5, 1988, pp. 6276-6280, “Regulation of the Enterotoxin B Gene in Staphylococcus aureus”, Gaskill, et al.
Neurosurg. Focus, Apr., 2001, vol. 10(4), “Bone graft substitutes for the promotion of spinal arthrodesis”, pp. 1-5, Helm, et al.
Journal of the Physical Society of Japan, vol. 77, No. 6, Jun. 2008, 064712, “Photoluminescence of the Dehydrated Ag—type Zeolite A Packed under Air”, pp. 064712-1-064712-7, Hoshino, et al.
Ann Nutr Metab., 1993, 37(5):245-252, 2 page abstract, “Impaired mechanical strength of bone in experimental copper deficiency”, Jonas, et al.
European Cells and Materials, vol. 8, 2004, pp. 37-57, “Concise Review of Mechanisms of Bacterial Adhesion to Biomaterials and of Techniques Used in Estimating Bacteria-Material Interactions”, Katsikogianni, et al.
J Bone Miner Res., Nov. 1992, vol. 7(11), pp. 1281-1289, 1 page Abstract, http://www.ncbi.nlm.nih.gov/pubmed/1334616, “Zeolite A increases proliferation, differentiation, and transforming growth factor beta production in normal adult human osteoblast-like cells in vitro”, Keeting, et al.
Medical Design Technology Online, Jan. 28, 2010, 5 pages, http://www.mdtmag.com/scripts/ShowPR.asp? Pubcode=0468,ACCT=0006305&Issue . . . , “Taking a PEEK at Material Options for Orthopedics”, Kinbrum.
National Institute of Standards and Technology (NIST) recommended practice guide, Special Publication 960-17, Sep. 2006, “Porosity and Specific Surface Area Measurements for Solid Materials”, 91 pages, Klobes, et al.
Clin. Orthop. Relat. Res., Nov.-Dec. 1981, vol. 161, pp. 154-162, 1 page Abstract, “Antibacterial and osteoinductive properties of demineralized bone matrix treated with silver”, Kramer, et al.
Medicaldevice-network.com, Jul. 2011, http://www.medicaldevice-network.com/features/feature128303, “PEEK performance: a next-generation biomaterial”, 5 pages, Kurtz.
Biomaterials, vol. 28, 2007, pp. 4845-4869, “PEEK biomaterials in trauma, orthopedic, and spinal implants”, Kurtz, et al.
The Journal of Nutrition, 2002, http://jn.nutrition.org/content/132/10/3135.full.pdf+html, Nutrient Requirements, “Bone Morphology, Strength and Density Are Compromised in Iron-Deficient Rats and Exacerbated by Calcium Restriction”, pp. 3135-3141, Medeiros, et al.
Journal of Polymer Science: Part B: Polymer Physics, 2004, vol. 42, pp. 1548-1563, “Poly(ether ether ketone)/Poly (aryl ether sulfone) Blends: Melt Rheological Behavior”, Nandan, et al.
Net Motion, Inc., copyright 2003, http://www.netmotion.com/htm—files/wh—properties.htm#chem, pp. 1-8, Downloaded from internet Mar. 1, 2013, All you want to know about Polyetheretherketone (PEEK), Chemical Resistance of Peek, Peek and Polymer chemical resistance.
Zinc Toxicity in Humans, 2007, Elsevier B.V. publication, pp. 1-7, Jerome Nriagu, School of Public Health, University of Michigan.
29th Edition of the Kunststoff Taschenbuch, 2004, pp. 514-517, Oberbach, et al.
BMC Musculoskeletal Disorders, 2013, 14:187, http://www.biomedcentral.com/1471-2474/14/187, 11 pages, “Staphylococcus aureus biofilms decrease osteoblast viability, inhibits osteogenic differentiation, and increases bone resorption in vitro”, Sanchez, Jr., et al.
J. Phys. Chem. A, 2000, vol. 104, pp. 7473-7483, “Colors of Ag+—Exchanged Zeolite A.”, Seifert, et al.
Rothman-Simeone-The Spine, 6th Edition, vol. II, Chapter 98, Garfin S., ed., “Postoperative Spinal Infections”, 53 pages, Smith, et al.
United States Environmental Protection Agency, Silver-Copper Zeolite Data Review, Feb. 15, 1994, 3 pages.
VICI AG International, 2013, VICI JOUR-Technical Support, Chemical Resistance of PEEK and Other Polymers, Chart displaying PEEK and Polymer Chemical Resistance, 3 pages.
The Structure and Synthesis of Zeolite Molecular Sieves, Jilin University Press, Aug. 1987, 1st Edition, pp. 6 and 3, 4 pages, Xu, et al.
“Opisanie tseolita i ego svoystv”, Aug. 4, 2004, https://web.archive.org/web/20040804124452/http://www.ceolit.smila.com/op.htm Apr. 8, 2004, 3 pages.
Office Action--Restriction—mailed Jan. 23, 2014 in co-pending U.S. Appl. No. 13/260,571.
Office Action mailed May 12, 2014 in co-pending U.S. Appl. No. 13/260,571.
Final rejection mailed Oct. 16, 2014 in co-pending U.S. Appl. No. 13/260,571.
Office action mailed Apr. 22, 2015 in co-pending U.S. Appl. No. 13/260,571.
Final rejection mailed Nov. 17, 2015 in co-pending U.S. Appl. No. 13/260,571.
Office Action mailed Jan. 10, 2013 in co-pending U.S. Appl. No. 13/511,176.
Final Rejection mailed Oct. 23, 2013 in co-pending U.S. Appl. No. 13/511,176.
Office Action mailed May 20, 2014 in co-pending U.S. Appl. No. 13/511,176.
Final Rejection mailed Jan. 5, 2015 in co-pending U.S. Appl. No. 13/511,176.
Office Action mailed Mar. 2, 2016 in co-pending U.S. Appl. No. 13/511,176.
Related Publications (1)
Number Date Country
20150342747 A1 Dec 2015 US
Provisional Applications (1)
Number Date Country
61332403 May 2010 US
Continuations (1)
Number Date Country
Parent 13696346 US
Child 14823063 US